Big picture - Why invest in Physiomics Plc
Physiomics Plc Snapshot
- Predicting inhibition ratios for compounds with >1 target
- Mechanistic modelling to validate targets and predict effects of candidate drugs
- Pathway models to understand detailed mechanism of action
- Ranking compounds and schedules for development progression
- Determining optimal biologically effective dose in mice or humans
- Optimising regimes for dose and timing to achieve maximal efficacy Optimising regimes to delay emergence of resistance
- Translation to and optimisation of regimes for new indications
- Predicting effects of radiation/ drug combinations
- Predicting effects of immune and traditional therapy combinations
Dr Paul Harper
Dr Paul Harper has over 35 years’ experience in the life sciences industry covering both drug development and medical devices. He is an NED of Reneuron Holdings plc, an AIM quoted company. In addition, he is an adviser to the Board of CamStent Ltd.
Paul has served as Chairman of Oval Medical Technologies and of Sareum plc, Chief Executive of Cambridge Antibody Technology Limited, and founded Provensis Limited. He has also served as Corporate Development Director of Unipath Limited, then the medical diagnostics business of Unilever PLC, and as Director of Research and Development for Johnson & Johnson Limited.
Formerly head of Antimicrobial Chemotherapy for Glaxo PLC, Paul has a PhD in Molecular Virology and is the author of over 50 publications.
Dr Jim Millen
Chief Executive Officer
Dr Jim Millen joined Physiomics in April 2016, bringing over 15 years’ experience in pharmaceuticals and biotechnology gained at a number of blue chip global companies as well as smaller UK-based organisations.
At Allergan, Jim was responsible for corporate development in its Europe, Africa and Middle East region where he was pivotal in expanding the company’s geographical footprint before moving to a senior role responsible for commercial strategy and market access. Prior to that, at GSK, Jim held business development roles of increasing responsibility including within the company’s innovative Centre of Excellence for External Drug Discovery. In the last 18 months Jim has supported a number of smaller companies in fund raising and strategic partnering activities. Over the course of his career he has completed an array of deals worth many hundreds of millions of dollars, spanning licencing, acquisition, divestment, development and commercialisation.
Jim studied medicine at Queens’ College, Cambridge University and qualified as a doctor from the London Medical School. He holds an MBA from INSEAD.
Dr Christophe Chassagnole
Chief Operating Officer
Dr Christophe Chassagnole has been involved in systems biology and bio-computing projects since the mid-nineties, with experience in both academic and industrial environments. His Doctorate was achieved at the Victor Segalen-Bordeaux II University, and then he held a post doctorate position with IBVT at Stuttgart University.
Before Joining Physiomics Dr Chassagnole worked in France as a senior researcher for CRITT Bio-Industries (Toulouse) for 3 years. He joined Physiomics in May 2004 as project leader to develop the model portfolio of the company. He was appointed Chief Operating Officer of Physiomics in May 2007.
Physiomics is listed on the AIM market under symbol PYC. Please click on the London Stock Exchange symbol to view recent share price and other market information.
“Trade mark of London Stock Exchange plc”
Physiomics shares are not traded on any other exchanges and there is no restriction on the transfer of shares. The total number of ordinary shares in issue is: 71,910,394.
Not in public hands: 63.95% of which 62.60% are held in nominee accounts.
Significant Shareholders as at 7th June 2018
|Interactive Investor Services||23.20%|
|Hargreaves Lansdown (Nominees)||17.17%|
|Barclays Direct Investing Nominees||11.75%|
|HSDL Nominees Limited||10.49%|
|Peel Hunt Holdings Limited||7.99%|
|HSBC Client Holdings Nominee (UK)||3.44%|
Document Last Updated: 7th June 2018